Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study
Phase 3positiveLunsumioPositive
AI Analysis
Summary
Roche announced that its Lunsumio-based regimen achieved significant improvement in progression-free survival in the Phase 3 CELESTIMO trial for follicular lymphoma treatment.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Significantly improved progression-free survival
Importance:8/10
Sentiment:
0.85
Phase 3 DataPositive Trial ResultOncologyHematologic MalignancyProgression-Free Survival
Related Companies
Read the original article
Published by yahoo_finance on September 17, 2026 5:00 AM